Skip to main content

COVID-19 Topic Center

News

News
Cumulative doses of phototherapy and related costs varied greatly among seven skin diseases, researchers highlighted in a new study.
News
A new report from the Government Accountability Office casts doubt on whether insurers are abiding by federal law requiring parity in insurance coverage, which forbids health plans from passing along more of the bill for mental health care to patients than they would for medical or surgical care.
News
A 35-year-old man with severe erythrodermic atopic dermatitis experienced clearance of his disease after 4 months of adding rescue tofacitinib to dupilumab therapy, according to a recent case report.
News
“Because persistence with the same anti-TNF drug in second-line treatment decreases the overall disease-associated costs compared with non-persistence, this aspect … merits consideration by physicians and payers when choosing a biological drug,” researchers wrote.
News
Researchers recently conducted a network meta-analysis and found treatment with guselkumab for psoriatic arthritis improved patient outcomes.
News
Humana sharply disputed the findings of the audit, and a spokesperson for the company said Humana will work with Medicare officials “to resolve this review,” and noted the recommendations “do not represent final determinations, and Humana will have the right to appeal.”  
News
In a new review article published online in Blood Cancer Journal, experts from the Lymphoma Research Foundation, Mayo Clinic Foundation, and Memorial Sloan-Kettering Cancer Center provide an in-depth review of new therapies recently approved by the FDA for the treatment of patients with DLBCL.
News
“Publications have shown the positive effect of therapeutic patient education on the course of the disease, the prevention of complications, and the autonomy and quality of patient life,” researchers wrote.
News
“Estimating the lifetime costs of managing HIV is useful for budgetary planning and to ensure HIV management is affordable for all,” the study concluded.
News
The cost burden of standard of care for patients with spinal muscular atrophy is substantial, and at current prices approved disease-modifying drugs for the condition have high cost-effectiveness ratios when delivered after symptom onset.
Back to Top